Inhibitors of Angiotensin-converting Enzyme or Blockers of Angiotensin-2 Receptor in COVID-19 Patients with Comorbid Cardiovascular or Pulmonary Diseases
{"title":"Inhibitors of Angiotensin-converting Enzyme or Blockers of Angiotensin-2 Receptor in COVID-19 Patients with Comorbid Cardiovascular or Pulmonary Diseases","authors":"F. Rahimi, A. Talebi Bezmin abadi","doi":"10.32598/RMM.8.3.851.6","DOIUrl":null,"url":null,"abstract":"n January 2020, the World Health Organization (WHO) announced the COVID-19 outbreak, caused by SARS-CoV-2, a publichealth emergency [1]. Following the skyrocketing spread of SARS-CoV-2 into more than 210 countries, diverse clinical strategies have been urgently explored against the COVID-19 pandemic while a magic-bullet antiviral vaccine or treatment is unavailable [2]. Although the clinical features of COVID-19 and the epidemiological characteristics of the pandemic have been described, COVID-19 has seemingly evolved, and its new symptoms and associations are being reported over time [3-7]. Nevertheless, SARS-CoV-2 is extremely contagious and new to the human immune system; thus, everyone is vulnerable.","PeriodicalId":30778,"journal":{"name":"Research in Molecular Medicine","volume":"8 1","pages":"103-106"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Molecular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/RMM.8.3.851.6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
n January 2020, the World Health Organization (WHO) announced the COVID-19 outbreak, caused by SARS-CoV-2, a publichealth emergency [1]. Following the skyrocketing spread of SARS-CoV-2 into more than 210 countries, diverse clinical strategies have been urgently explored against the COVID-19 pandemic while a magic-bullet antiviral vaccine or treatment is unavailable [2]. Although the clinical features of COVID-19 and the epidemiological characteristics of the pandemic have been described, COVID-19 has seemingly evolved, and its new symptoms and associations are being reported over time [3-7]. Nevertheless, SARS-CoV-2 is extremely contagious and new to the human immune system; thus, everyone is vulnerable.